Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion

T D Wardle, L Hall, L A Turnberg

Abstract

Metabolites of arachidonic acid have been implicated in the pathophysiology of ulcerative colitis – they can stimulate intestinal secretion, increase mucosal blood flow, and influence smooth muscle activity. The influence on the mucosal transport function of culture medium in which colonic mucosal biopsy specimens had been incubated was investigated using rat stripped distal colonic mucosa in vitro as the assay system. Colonic tissue from patients with colitis and from control subjects was cultured. Medium from inflamed tissue contained more prostaglandin E₂ (PGE₂) and leukotriene D₄ (LTD₄) and evoked a greater electrical (secretory) response in rat colonic mucosa than control tissue medium. In inflamed tissue, cyclo-oxygenase inhibition (indomethacin) attenuated PGE₂ but increased LTD₄ production; conversely lipoxygenase inhibition (ICI 207968) inhibited LTD₄ production but enhanced PGE₂ output. Each inhibitor alone enhanced the electrical response in the rat colon. Inhibition of both enzymes (indomethacin plus ICI 207968) caused a fall in both PGE₂ (82%) and LTD₄ (89%) production and in the electrical response (57%). Inflamed tissue treated with a phospholipase A₂ inhibitor (mepacrine) produced less PGE₂, LTD₄, and electrical responses when compared with inflamed tissue, either untreated (91%, 92%, and 79% respectively) or treated with cyclo-oxygenase and lipoxygenase inhibition. Incubation with bradykinin stimulated eicosanoid release and electrical response, while a bradykinin antagonist caused a modest inhibition. Analysis of these observations suggests that a combination of arachidonic acid derivatives accounts for about half the secretory response. Other products of phospholipase A₂ activity are probably responsible for much of the remainder, leaving up to 20% the result of types of mediator not determined in this study.

(Gut 1993; 34: 503–508)

High concentrations of prostaglandins and leukotrienes have been found in stool water and colonic mucosal biopsy specimens from patients with ulcerative colitis^{1–7} and these have been implicated in the pathophysiology of inflammatory bowel disease. They may not only be involved in the mediation and amplification of the immune response but several have also been shown to stimulate mucosal secretion, increase mucosal blood flow, and influence smooth muscle

activity, each of which may be relevant to the diarrhoea that these patients suffer.^{8–10}

Because such a wide variety of inflammatory mediators is liberated in colitis it is difficult to ascertain which, either alone or in combination, might be responsible for the associated changes in intestinal function.

We describe studies of the influence on intestinal secretion of inflammatory mediators released into the medium in which biopsy specimens of inflamed colonic mucosa were cultured. We used rat colonic mucosa in vitro as our 'assay' system for determining secretory responses. Studies of the effect of a variety of inhibitors on these responses, and on the release of a number of mediators, have allowed us to show that a combination of prostaglandins and leukotrienes are probably responsible for over half of the secretory response, and that other products of phospholipase A₂ activity are probably responsible for much of the remainder.

Methods

PATIENT DETAILS

Thirty patients underwent colonoscopy after bowel preparation. Preparation consisted of a three day low residue diet, and one day before the examination a combination of X prep (purified senna extract; 1 ml/kg body weight) and 10% mannitol (500 ml) modified according to the patient's symptoms.

Ten of the patients (four men and six women, median age 36 years) had a clinical diagnosis of irritable bowel syndrome. They all had endoscopically and histologically normal mucosa.

Twenty patients (13 men and seven women median age 39.4 years) with active distal proctosigmoiditis had biopsy specimens taken from inflamed mucosa. Six patients were taking mesalazine (400 mg three times daily), four prednisolone (5 to 15 mg once daily), and seven topical steroids at the time of colonoscopy. All biopsy specimens were taken with non-spiked forceps to minimise tissue trauma.

Ethical approval for these studies was given by the Salford Health Authority Ethics Committee.

EXPLANT CULTURE

A series of cultures was performed for each patient. Mucosal biopsy specimens were immediately placed in transport medium (L15, with added penicillin G and streptomycin sulphate), transferred to the laboratory, washed gently three times in the L15 medium, carefully

Department of Medicine
and the Epithelial
Membrane Research
Centre, University of
Manchester, Hope
Hospital, Salford,
Manchester
T D Wardle
L Hall
L A Turnberg

Correspondence to:
T D Wardle, Department of
Medicine, Clinical Sciences
Building, Hope Hospital,
Eccles Old Road, Salford M6
8HD.

Accepted for publication
31 August 1992

blotted, weighed (range 3–8 mg), and placed in a 5 cm culture dish containing 1 ml of culture medium (CMRL) 1066, plus glucose 5 µg/ml, methionine 1 µM/ml, Tris buffer 20 mM, glutamine 3 µM/ml, β-retinyl acetate 1 µg/ml, penicillin G 100 units/ml, streptomycin sulphate 100 µg/ml, gentamicin 50 µg/ml, and amphotericin β 0.25 µg/ml. Individual mucosal biopsy specimens were cultured with either no additives or in the presence of one of the following: indomethacin (cyclo-oxygenase inhibitor); ICI 207968 (lipoxygenase inhibitor); a combination of indomethacin and ICI 207968; mepacrine (phospholipase A₂ inhibitor) (all at 10⁻⁵M); and bradykinin, or des arg leu bradykinin (bradykinin antagonist) (both at 10⁻⁸M). The culture dishes were placed in a humidified chamber maintained at 37°C, supplied with a mixture of 95% oxygen/5% carbon dioxide, and rotated at 10 cycles/minute. After 4 hours of culture the medium was removed and divided into three aliquots for measurement of PGE₂, LTD₄, and electrical responses in rat colonic mucosa.

EICOSANOID MEASUREMENTS

PGE₂ and LTD₄ were measured using commercially available radioimmunoassay kits (PGE₂, du Pont UK, Stevenage, Herts, UK¹¹; LTD₄, Amersham, Aylesbury, Bucks, UK¹²). Eicosanoids were extracted from the culture medium using solid phase sorbent extraction (mini columns, Amersham). The resultant sample competes with a fixed amount of radioactively labelled eicosanoid analogue (iodinated PGE₂ or tritiated LTD₄) for a limited number of binding sites. The sample PGE₂ antibody complex is separated from the free antigen by polyethylene glycol precipitation and centrifugation, and then counted in a gamma counter. Separation of the leukotriene bound antibody complex was facilitated using dextran coated charcoal. After centrifugation the quantity of antibody bound radioactive ligand was measured on a beta counter.

Assay performance characteristics

Assay performance characteristics were as follows. PGE₂ intra and interassay variation values were 11 pg/ml and 60 pg/ml respectively; recovery was 96% and sensitivity 0.8 pg/ml. Cross reactivity (non-E prostaglandins) was <0.4%.¹¹ LTD₄ intra and interassay variation values were 14 pg/ml and 39 pg/ml respectively; recovery was 91% and sensitivity 5 pg/ml. Cross reactivity (non-sulphidopeptide leukotrienes) was <0.001%.¹²

Eicosanoid concentrations were calculated by interpolation from a standard curve. All results were expressed in pmol/mg wet tissue/hour.

RAT DISTAL COLON PREPARATION

An *in vitro* technique modified from that of Ussing and Zerahn was used.¹³ Unfasted male Sprague-Dawley rats were killed and the distal colon was removed immediately and bathed in

oxygenated buffer. Muscle layers were stripped and the two most distal pieces of mucosa were mounted as sheets, between Perspex flux chambers, with a surface area of 0.64 cm² (VT Plastics Ltd, Warrington, UK).

The spontaneous, basal transmucosal potential difference (PD) was measured, on a high impedance digital voltmeter via fine tipped electrode bridges (3M KCl in 3% agar) connected to matched calomel half cells. The short circuit current (I_{sc}) was delivered by silver/silver chloride electrodes via 1M NaCl in 1% agar bridges. The electrodes were connected to a voltage clamp for automatic short circuiting. The clamp was corrected for fluid resistance between the PD sensing bridges. Tissue conductance and resistance were calculated from the PD and I_{sc} according to Ohm's law.

Each mucosal sheet was bathed on both sides with 5 ml of isotonic buffer containing: Na 146 mM; K 4.2 mM; Cl 125.8 mM; HCO₃ 26.6 mM; H₂PO₄ 0.2 mM; HPO₄ 1.2 mM; Ca 1.2 mM; Mg 1.2 mM; and glucose 10 mM, at pH 7.4. The bathing media were stirred and oxygenated via a bubble lift system using 95% O₂/5% CO₂ and were maintained at a constant temperature of 37°C.

Culture medium (100 µl) was added to the bathing fluid on the serosal aspect of rat colonic mucosa after electrical stability had been reached, usually after 30 minutes.

SECRETORY AGONISTS

Eicosanoids

PGE₂ or LTD₄, in final concentrations ranging from 10⁻¹⁰ to 10⁻⁴M, were added to the serosal aspect of stripped rat distal colon. Changes in PD, I_{sc}, and resistance were recorded.

Culture medium

Culture medium (100 µl) was added to the serosal aspect of stripped rat colon and electrical measurements, as described above, were recorded. The process was repeated using either medium incubated with the inhibitors to act as controls or medium from biopsy specimens cultured with the inhibitors as detailed above. The resultant rise in I_{sc} was compared with the PGE₂ and LTD₄ dose response curves.

CHEMICALS

The 5 lipoxygenase inhibitor, ICI 207968, was kindly supplied by Dr R Dowell, Imperial Chemical Company, Alderley Edge, UK. Prostaglandin E₂, bradykinin, des arg leu bradykinin, mepacrine, and indomethacin were obtained from Sigma Chemical Co, Poole, Dorset, UK. LTD₄ was purchased from Cascade Biochem Ltd, University of Reading, Berks, UK.

CALCULATIONS

All values are expressed as the mean (SEM). Statistical comparisons were performed using paired and unpaired *t* tests.¹⁴

Figure 1: Prostaglandins E₂ production by cultured colonic mucosa (pmol and pg/mg wet tissue/hour mean (SEM)). *n*=10 cultures/column. C=control mucosa; I=inflamed mucosa; CO=cyclo-oxygenase inhibition (indomethacin); LO=lipoxygenase inhibition (ICI 207968). *Significantly different from untreated control tissue, *p*<0.01; **significantly different from untreated inflamed tissue, *p*<0.01.

Figure 2: Leukotriene D₄ production by colonic mucosa (pmol and pg/mg wet tissue/hour mean (SEM)). *n*=10 cultures/column. C=control mucosa; I=inflamed mucosa; CO=cyclo-oxygenase inhibition (indomethacin); LO=lipoxygenase inhibition (ICI 207968). *Significantly different from untreated control tissue, *p*<0.01; **significantly different from untreated inflamed tissue, *p*<0.01.

Figure 3: The effect of inflammatory mediators liberated from cultured colonic tissue on the secretory response of rat colonic mucosa; the effect of agonists and antagonists. Isc=short circuit current (μA.cm⁻², mean (SEM)). *n*=4 pieces of stripped rat distal colonic mucosa/column. M=medium alone, C=control mucosa; I=inflamed mucosa; CO=cyclo-oxygenase inhibition (indomethacin); LO=lipoxygenase inhibition (ICI 207968). *Significantly different from untreated control tissue, *p*<0.01; **significantly different from untreated inflamed tissue, *p*<0.01.

Results

EICOSANOID MEASUREMENTS

Inflamed tissue produced significantly more PGE₂ and LTD₄ than control tissue (2.79 (0.11) v 0.54 (0.04); 1.73 (0.11) v 0.44 (0.04) respectively, *p*<0.01) (all values are given in pmol/mg wet tissue weight/hour). The production rate of eicosanoids is also expressed graphically in both pmol and pg/mg wet tissue weight/hour; for example in inflamed tissue PGE₂ production is 2.79 pmol or 1012 pg/mg wet weight/hour and LTD₄ is 1.73 pmol or 837 pg/mg wet weight/hour. (Figs 1 and 2). Cyclo-oxygenase inhibition (indomethacin, 10⁻⁵M) significantly reduced PGE₂ production when values were compared with those in the untreated groups (inflamed 0.511 (0.06) v 2.79 (0.11); control 0.17 (0.02) v 0.54 (0.04); *p*<0.01), whereas the yield of LTD₄ was increased (inflamed 2.4 (0.17) v 1.73 (0.11); control 0.74 (0.07) v 0.44 (0.04), *p*<0.01).

A significant increase in PGE₂ production, by all groups, followed lipoxygenase inhibition (ICI 207968, 10⁻⁵M) (inflamed 3.9 (0.22) v 2.79 (0.11); control 0.91 (0.13) v 0.54 (0.04), *p*<0.01), while LTD₄ generation was reduced (inflamed 0.16 (0.07) v 1.73 (0.11); control 0.1 (0.01) v 0.44 (0.04), *p*<0.01).

Combined inhibition of cyclo-oxygenase and lipoxygenase produced almost identical PGE₂ results to those found after indomethacin alone (Fig 1), and LTD₄ results to those found after ICI 207968 alone (Fig 2).

In inflamed tissue, phospholipase A₂ inhibition (mepacrine) appreciably reduced the production of both PGE₂ and LTD₄ when compared with values in untreated mucosa (PGE₂ 0.21 (0.03) v 2.79 (0.11); LTD₄ 0.14 (0.04) v 1.73 (0.11) respectively; *p*<0.001). The reduction after mepacrine was also greater than that after combined cyclo-oxygenase and lipoxygenase inhibition (PGE₂ 0.21 (0.03) v 0.5 (0.05); LTD₄ 0.14 (0.04) v 0.19 (0.03) respectively, *p*<0.04). Mepacrine also significantly attenuated eicosanoid output by control tissue (PGE₂ 0.11 (0.014) v 0.54 (0.04); LTD₄ 0.1 (0.08) v 0.44 (0.04); *p*<0.01).

In comparison with the untreated group, bradykinin stimulated a significant increase in both PGE₂ production (control 1.1 (0.18) v 0.54 (0.04); inflamed 4.1 (0.24) v 2.79 (0.11); *p*<0.001) and LTD₄ production (control 1.1 (0.12) v 0.44 (0.04); inflamed 4.1 (0.17) v 1.7 (0.11); *p*<0.001).

Inhibition of bradykinin resulted in a fall in PGE₂ and LTD₄ generation by all groups but only the reduction found in the inflamed group reached statistical significance (inflamed PGE₂ 2.3 (0.14) v 2.79 (0.11); LTD₄ 1.1 (0.1) v 1.73 (0.11) respectively; *p*<0.01, control PGE₂ 0.34 (0.05) v 0.54 (0.04); LTD₄ 0.29 (0.05) v 0.44 (0.04); NS).

EFFECT OF CULTURE MEDIUM ON STRIPPED RAT DISTAL COLON

Fresh culture medium applied to the serosal half chamber did not produce any change in baseline electrical activity (Fig 3). Culture medium incubated with the inhibitors did not influence

the basal *I*_{sc}. Culture fluid from inflamed tissue evoked a significantly larger *I*_{sc} increase than fluid from control mucosa (31 (2.6) *v* 6.3 (1.3) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.001$).

Cyclo-oxygenase inhibition

Medium from control biopsy specimens cultured with or without indomethacin produced similar rises in electrical measurements. However, a significantly greater increase in *I*_{sc} occurred with fluid derived from inflamed mucosal biopsy specimens treated with indomethacin, compared with the untreated group (40 (2.5) *v* 31 (2.6) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.01$).

Lipoxygenase inhibition

Lipoxygenase inhibition with ICI 207968 did not influence the modest rise in electrical activity seen with the control biopsy medium. However, after lipoxygenase inhibition medium from inflamed tissue produced a significantly greater *I*_{sc} response than that from untreated control tissues (43.5 (5) *v* 31 (2.6) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.01$).

Combined lipoxygenase and cyclo-oxygenase inhibition

There was no significant difference between the short circuit response evoked by culture medium from untreated control tissue and control biopsy specimens exposed to combined cyclo-oxygenase and lipoxygenase inhibition. Culture medium from inflamed tissue treated in the same way, however, produced a significantly lower *I*_{sc} response than medium from untreated tissues (13.4 (2.1) *v* 31 (2.6) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.005$).

Phospholipase A₂ inhibition

Control biopsy specimens incubated with mepacrine produced media which provoked a significantly smaller *I*_{sc} response than untreated mucosal media (2.5 (1) *v* 6.3 (1.3) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.01$). Medium from inflamed tissue exposed to mepacrine evoked an *I*_{sc} response that was significantly lower than that from either medium from untreated tissue or from tissues exposed to

the combined effects of cyclo-oxygenase and lipoxygenase inhibition. (6.4 (1.1) *v* 31 (2.6) and 13.4 (2.1) $\mu\text{A}\cdot\text{cm}^{-2}$; respectively, $p < 0.005$).

Bradykinin agonist

The addition of bradykinin to the culture medium bathing both types of tissue produced a highly significant increase in *I*_{sc} compared with values in the untreated groups (control 17.5 (2.8) *v* 6.3 (1.3); inflamed 66.1 (4.9) *v* 31 (2.6) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.001$).

Bradykinin antagonism

Bradykinin receptor blockade produced a fall in the *I*_{sc} for both tissue types, but only in the inflamed group did the change reach statistical significance (31 (2.6) *v* 19.3 (3.1) $\mu\text{A}\cdot\text{cm}^{-2}$; $p < 0.01$).

DOSE RESPONSE CURVES

PGE₂

PGE₂ added to the serosal, but not the mucosal, side of stripped rat distal colon caused a rapid increase in *I*_{sc}, which peaked after 2½ to 3 minutes. The dose response curve for PGE₂ gave an EC₅₀ of $5 \times 10^{-7}\text{M}$ (Fig 4). PGE₂ generated a parallel but smaller increase in PD and a modest rise in tissue conductance.

LTD₄

LTD₄ added to the serosal aspect of stripped rat distal colon, evoked a rapid rise in *I*_{sc}, which peaked after 2½ minutes (Fig 5). The EC₅₀ for this response was $8 \times 10^{-7}\text{M}$. The transmucosal PD also increased while conductance rose to a modest extent.

Combined PGE₂ and LTD₄

At the peak *I*_{sc} response to PGE₂ at 10^{-5}M and 10^{-8}M , LTD₄ 10^{-5}M and 10^{-8}M respectively were added to the serosal chamber. The combined *I*_{sc} for 10^{-5}M was $43.4 \mu\text{A}\cdot\text{cm}^2$ and for 10^{-8}M it was $20.8 \mu\text{A}\cdot\text{cm}^2$. These values were not significantly different from those expected from the dose response curves ($41.5 \mu\text{A}\cdot\text{cm}^2$:

Figure 4: Prostaglandin E₂ dose response curve in stripped rat distal colon. Values are mean (SEM). Number of rat mucosal preparations under each point.

Figure 5: Leukotriene D₄ dose response curve in stripped rat distal colon. Values mean (SEM). Number of rat mucosal preparations under each point.

18.5 $\mu\text{A}\cdot\text{cm}^2$ respectively – that is, there was no evidence of potentiation at either maximal or half maximal concentration.

Discussion

In these studies we have shown that inflamed tissue releases more eicosanoids into the culture medium than control mucosa, and that medium from any of the tissues will evoke an electrical response in stripped rat distal colon. A rise in electrical potential difference and *I*_{sc} in this mucosal preparation is associated with secretion of chloride ions and we have used a rise in electrical measurements as a proxy for anion secretion.

Inflamed tissue produced significantly more PGE₂ and LTD₄ than control mucosa, but the difference was not as great as that shown by rectal dialysis.^{15,16} Although the degree of indomethacin induced cyclo-oxygenase inhibition is variable,¹⁷ all groups showed significant attenuation of PGE₂ production and a reciprocal, significant increase in LTD₄ generation. Conversely, inhibition of lipoxygenase activity resulted in a suppression of LTD₄ generation and stimulation of PGE₂ synthesis. Presumably, the increased availability of arachidonate for one enzyme system when the alternative route was blocked is responsible for these reciprocal effects on PGE₂ and LTD₄ production.

Because PGE₂ and LTD₄ have each been shown to stimulate intestinal secretion^{18–21} it is not surprising to find that inhibiting the production of one of these did not reduce the secretory (electrical) response to medium, in which a reciprocal rise in the other had occurred. More difficult to explain is the *greater* *I*_{sc} response to medium in which one stimulant was appreciably depressed while the other was only moderately increased. It is possible that the inhibition of the lipoxygenase or cyclo-oxygenase pathways caused the synthesis of more potent secretagogues than simply the two measured in this study. Other potential contenders for this role include prostacyclin, a more potent secretagogue than PGE₂²² in the case of lipoxygenase inhibition, and other leukotrienes (B₄, C₄) in the case of cyclo-oxygenase inhibition.²¹

This type of analysis leads to the conclusion that there is a finely balanced production of the major metabolites of arachidonic acid and that subtle alterations in the relative activities of the enzymes concerned will cause variable responses. Blockade of a major pathway, as in this study, can thus produce unpredictable changes in functional responses. The failure of early attempts to treat ulcerative colitis with cyclo-oxygenase inhibitors may be explicable on this basis.^{23–27}

Simultaneous blockade of cyclo-oxygenase and lipoxygenase pathways reduced both PGE₂ and LTD₄ production, as might be expected, and also attenuated the electrical response of rat colonic mucosa to this culture medium. However, the 82% reduction in PGE₂ production and the 89% reduction in LTD₄ production was associated with only a 57% reduction in transmucosal *I*_{sc} suggesting that other factors are probably involved in provoking the electrical

response. One possibility is that potentiation between the effects of low concentrations of these metabolites might occur. Such a potentiation would have to be greater at low than at high concentrations to account for this observation and we did not find evidence of potentiation between PGE₂ and LTD₄ in our study. Thus, this seems a less likely explanation than the simultaneous generation of other types of secretory agonists. In favour of this are the results of phospholipase A₂ inhibition with mepacrine. Here blockade of the enzyme responsible for arachidonic acid liberation caused a much greater fall in the electrical response of rat colonic mucosa (from 57% after combined lipoxygenase and cyclo-oxygenase inhibition to 79% after phospholipase A₂ inhibition). PGE₂ and LTD₄ production were also further reduced (82% to 92% and 89% to 91% respectively), but these falls were much less impressive than the fall in *I*_{sc}.

It is interesting to compare the electrical responses to culture media (with their measured eicosanoid concentrations) with the dose response curves for PGE₂ and LTD₄. It is clear that the concentrations of both eicosanoids measured in the culture media are much lower than those that might be expected to provoke the electrical responses which were observed if their effects were simply additive. The mean eicosanoid concentrations derived from culture medium from inflamed tissue were in the order of $4.45 \times 10^{-11}\text{M}$ for PGE₂, and $2.77 \times 10^{-11}\text{M}$ for LTD₄. As indicated by the dose response curves, no change in *I*_{sc} would be expected with these amounts, even if these concentrations were summated. The mean rise in *I*_{sc} evoked by medium from inflamed cultures was 30 $\mu\text{A}\cdot\text{cm}^{-2}$ which would be expected at concentrations of some 10^{-5}M PGE₂, or 10^{-6}M LTD₄, if these were the only mediators present. Clearly other mediators must also be involved in the electrical response, but the degree of inhibition by mepacrine (79%) suggests that most are likely to be products of phospholipase A₂ activation.

It may be concluded from these observations that cyclo-oxygenase and lipoxygenase products account for most (57%) of the electrical response induced by medium from cultured colonic mucosa. Only PGE₂ and LTD₄ were measured in these studies and since they could only be held responsible for part of the response, other cyclo-oxygenase and lipoxygenase products are likely to have contributed.

Moreover, other phospholipase A₂ metabolites are probably responsible for a further 22% of the electrical response. It seems most likely that this is due to a non-arachidonic acid derivative, platelet activating factor being a reasonable contender for this role.

The remaining 21% of the electrical response produced by medium from cultured inflamed biopsy specimens could be caused by a variety of other mediators such as histamine, 5-hydroxytryptamine and, possibly, transmitters liberated from neural tissues.

Because much of the electrical, secretory response to culture medium could be ascribed to the release of products of phospholipase A₂ activity it was of interest to investigate the

influence of one potentially important stimulus to phospholipase A₂ activity. Inflammatory cells, in particular macrophages have receptors for bradykinin, a potent secretagogue acting almost entirely by stimulating arachidonic acid release via phospholipase A₂ activation. Its effect on intestinal mucosa, at least in the rat ileum, is indirect, its site of action being on sub-epithelial cells.^{28,29} In our study bradykinin caused a noticeable rise in eicosanoid release from control and inflamed biopsy specimens and culture medium from these caused a greater rise in Isc in the rat colonic mucosa model. Bradykinin receptor blockade with des arg leu bradykinin caused a fall in eicosanoid output and the associated Isc response, suggesting that bradykinin may be a stimulus to endogenous phospholipase A₂ activity in biopsy specimens of normal and inflamed colonic mucosa. The fall in PGE₂ and LTD₄ production after bradykinin receptor blockade was, however, less than that found after direct phospholipase A₂ inhibition with mepacrine or after combined lipoxygenase and cyclo-oxygenase inhibition. Reasons for this smaller effect include the possibility that receptor blockade with des arg leu bradykinin was incomplete in these specimens. It is also likely that the other stimuli to phospholipase A₂ activity such as interleukin 1,³⁰ interleukin 8, and other monocyte derived growth factors,³¹ are liberated in these tissues.

Although we have focussed on the secretory effects of these inflammatory mediators, it is clear that they are likely to have a number of other effects that will contribute to the pathophysiology of the disease. The effects, on secretion, described here, however, provide one indicator of the tissue response in inflammatory disease.

In conclusion, we have provided evidence in favour of the view that eicosanoids are the major inflammatory mediators causing secretory responses in colonic mucosa and that their production can be significantly reduced by combined cyclo-oxygenase and lipoxygenase inhibition or by mepacrine or by a bradykinin antagonist. The maximal reduction in eicosanoid release and secretory response was achieved with mepacrine and this may warrant further clinical evaluation of its therapeutic role in inflammatory bowel disease. Care should be taken in the assessment of drugs which influence inflammatory mediator metabolic pathways since disturbance of these complex interactions and balances may produce unpredictable results.

We are grateful to Dr R Dowell of the Imperial Chemical Industries for donating the 5-lipoxygenase inhibitor. We are indebted to the Ileostomy Association for their financial support and interest in our work. We would also like to thank Carol McDonna for typing the manuscript.

- 1 Gould SR. Prostaglandins, Ulcerative colitis and sulphasalazine. *Lancet* 1975; ii: 988.
- 2 Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine. *Gastroenterology* 1978; 75: 638–40.

- 3 Sharon P, Stenson WF. Enhanced synthesis of leukotriene B₄ by colonic mucosa in inflammatory bowel disease. *Gastroenterology* 1984; 86: 435–60.
- 4 Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D. Enhanced thromboxane A₂ and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. *Gastroenterology* 1981; 81: 444–9.
- 5 Boughton-Smith NK, Hawkey CJ, Whittle BJR. Biosynthesis of lipoxygenase and cyclo-oxygenase products from ¹⁴C arachidonic acid by human colonic mucosa. *Gut* 1983; 24: 1176–86.
- 6 Peskar BM, Dreyling KW, Peskar BA, May B, Goebell H. Enhanced formation of sulfidopeptide leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. *Agents Action* 1986; 18: 381–3.
- 7 Wardle TD, Turnberg LA. Co-culture of colonic mucosa – a novel technique for investigating the role of soluble mediators in inflammatory bowel disease. *Gastroenterology* 1990; 98: A499.
- 8 Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa, are they important in its function, disease or treatment? *Gastroenterology* 1985; 89: 1162–88.
- 9 Rask-Madsen J. Eicosanoids and their role in the pathogenesis of diarrhoeal diseases. *Clin Gastro* 1986; 15: 545–66.
- 10 Bennett A, Eleg KG, Scholes GB. Effects of prostaglandin E₁ and E₂ on human, guinea pig and rat isolated small intestine. *Br J Pharm* 1968; 34: 630–8.
- 11 NEN Research. *Instruction manual for measurement of prostaglandin E₂ in plasma and tissue samples*. 1988.
- 12 *Leukotriene C₄/D₄/E₄ assay system*. Hertford: Du Pont, Amersham: Amersham International, 1988.
- 13 Ussing HH, Zerahn K. Active transport of sodium as a source of the electric current in short circuited isolated frog skin. *Acta Physiol Scand* 1951; 23: 110–27.
- 14 Snedecor GW, Cochran WG. *Statistical methods*, 7th Edition. Ames, Iowa: Iowa State University, 1980.
- 15 Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Intra luminal colonic levels of arachidonic acid metabolites in ulcerative colitis. *Advances in Prostaglandin Thromboxane Leukotriene Research* 1987; 17: 347–52.
- 16 Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis and clostridium difficile colitis. *Gastroenterology* 1988; 95: 11–7.
- 17 Moore PK. Effect of drugs on arachidonic acid metabolism. In eds: *Prostanoids: pharmacological, physiological and clinical relevance*. Cambridge, Cambridge University Press, 1988, 41–68.
- 18 Smith PL, Montzka DP, McCafferty GP, Wasserman MA, Fondacaro JD. Effect of sulphidopeptide leukotrienes D₄ and E₄ on ileal ion transport in vitro in the rat and rabbit. *Am J Physiol* 1988; 255: G175–83.
- 19 Kimberg DV, Field M, Johnson J, Henderson A, Gershon E. Stimulation of intestinal mucosa adenylate cyclase by cholera enterotoxin and prostaglandin. *J Clin Invest* 1971; 50: 1218–30.
- 20 Field M, Musch MW, Steff JS. Role of prostaglandins in the regulation of intestinal electrolyte transport. *Prostaglandins* 1987; 21: 73–9.
- 21 Musch MW, Miller RJ, Field M, Siegel MI. Stimulation of colonic secretion by lipoxygenase metabolites of arachidonic acid. *Science* 1982; 217: 1255–6.
- 22 Moriarty K, Wardle T, Higgs NB, Tonge A, Warhurst G. Prostacyclin regulates secretion in mammalian colon via dual calcium and cyclic AMP dependent mechanisms – comparison with PGE₂. *Gastroenterology* 1990; 98: A549.
- 23 Gould SR, Brash AR, Conolly ME, Lennard-Jones JE. Studies of prostaglandins and sulfasalazine in ulcerative colitis. *Prostaglandins Med* 1981; 6: 165–82.
- 24 Gilat T, Ratan J, Rosen P, Peled Y. Prostaglandins and ulcerative colitis. *Gastroenterology* 1978; 76: 1083.
- 25 Campieri M, Lanfranchi GA, Bazzocchi G. Prostaglandins, indomethacin and ulcerative colitis. *Gastroenterology* 1980; 78: 193.
- 26 Rampton DS, Sladen GE. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. *Prostaglandins* 1987; 21: 417–25.
- 27 Rampton DS, Sladen GE. Relapse of ulcerative proctitis during treatment with non-steroidal anti-inflammatory drugs. *Postgrad Med J* 1981; 57: 297–9.
- 28 Warhurst G, Higgs NB, Lees M, Tonge A, Turnberg LA. Site and mechanisms of action of kinins in rat ileal mucosa. *Am J Physiol* 1987; 252: G293–300.
- 29 Lawson LD, Powell DW. Bradykinin stimulated eicosanoid synthesis and secretion by rabbit ileal components. *Am J Physiol* 1987; 252: G783–90.
- 30 Cominelli F, Nast CC, Dinarello CA, Gentilini P, Sipser RD. Regulation of eicosanoid production in rabbit colon by interleukin 1. *Gastroenterology* 1989; 97: 1400–5.
- 31 Cominelli F, Dinarello CA. Interleukin 1 in the pathogenesis of and protection from inflammatory bowel disease. *Biotherapy* 1989; 1; 369–75.